

Table 2. Free and total IGF-I and -II, as well as IGFBP-1, -2 and -3 results in euthyroid patients with active TED undergoing SM-a treatment (Rx) and in controls.

	Patients		Controls	P-value	
	Before Rx n = 21	After Rx n = 20	n = 19		
Free (F) IGF-I ($\mu\text{g/L}$)	0.67 (0.46)	0.64 (0.44)	0.85 (0.43)	0.43 ⁺	0.70*
Total (T) IGF-I ($\mu\text{g/L}$)	131 (61)	126 (55)	146 (51)	0.29	0.96
F IGF-II ($\mu\text{g/L}$)	1.45 (0.54)	1.52 (0.76)	1.53 (0.53)	0.75	0.94
T IGF-II ($\mu\text{g/L}$)	1056 (300)	1092 (310)	939 (197)	0.77	0.11
IGFBP-1 ($\mu\text{g/L}$)	33 (14)	45 (31)	44 (24)	0.07	0.09
IGFBP-2 ($\mu\text{g/L}$)	848 (377)	903 (409)	764 (316)	0.58	0.28
IGFBP-3 ($\mu\text{g/L}$)	3953 (1422)	3981 (1369)	3721 (1017)	0.48	0.12
&T IGF-I/IGFBP-3 (%) (molar ratio)	18.1 (23.3)	17.3 (21.9)	21.4 (27.3)	0.25	0.62
&T IGF-II/IGFBP-3 (%) (molar ratio)	145.7 (115.1)	149.6 (123.5)	130.0 (106.7)	0.31	0.36
F/T IGF-I (%)	0.47 (0.16)	0.48 (0.23)	0.61 (0.28)	0.97	0.18
F/T IGF-II (%)	0.19 (0.19)	0.18 (0.18)	0.16 (0.07)	0.78	0.22

&= The molar weight of IGFBP-3 is 42 KDa, and that of IGF-I and -II 7.7 KDa. Thus, to achieve the molar ratio, we calculated the molar concentrations of IGFBP-3 ($=\mu\text{g/l} / 42 \text{ nmol/l}$) and molar concentrations of IGF-I, -II ($=\mu\text{g/l} / 7.7 \text{ nmol/l}$)

⁺= Patients before vs patients after SM-a treatment

* = Patients before vs controls individuals

The data before therapy in patient and those of controls are adopted from Krassas GE, et al¹² by the permission of the Endocrine Society